IL6 and acute respiratory distress syndrome: Furthermore, recently, Raloxifene and Bazedoxifene were found to be capable of interfering with IL-6 signaling in severe COVID-19 patients, showing positive effects on Acute Respiratory Distress Syndrome [46].